Baidu
map

Oncogene:在CRPC中,KDM8/JMJD5作为AR和PKM2的共激活子参与了AR/EZH2网络和肿瘤代谢

2018-08-12 AlexYang MedSci原创

在进化到去雄抗性或者治疗抗性的历程中,前列腺癌细胞重新调整了雄性激素的响应来应对雄性激素水平的降低,并且针对营养的匮乏和缺氧条件进行代谢适应。AR(雄性激素受体)和PKM2(丙酮酸激酶M2)在这些过程中具有关键的作用。最近,有研究人员报道了KDM8/JMJD5,一个组蛋白赖氨酸脱甲基酶/脱氧酶,展现出了作为AR和PKM2的双激活剂特性,因此它也是去雄抗性和治疗抗性的潜在诱导因子。之前,研究人员展现

在进化到去雄抗性或者治疗抗性的历程中,前列腺癌细胞重新调整了雄性激素的响应来应对雄性激素水平的降低,并且针对营养的匮乏和缺氧条件进行代谢适应。AR(雄性激素受体)和PKM2(丙酮酸激酶M2)在这些过程中具有关键的作用。

最近,有研究人员报道了KDM8/JMJD5,一个组蛋白赖氨酸脱甲基酶/脱氧酶,展现出了作为AR和PKM2的双激活剂特性,因此它也是去雄抗性和治疗抗性的潜在诱导因子。之前,研究人员展现了KDM8在乳腺癌细胞中参与了细胞周期和肿瘤代谢的调控,而其在前列腺癌中的作用还未进行阐释。在这次研究中,他们阐释了KDM8在前列腺癌中的致瘤特性,包括与AR的直接互作来影响雄激素响应以及与PKM2直接互作来调控肿瘤代谢。研究发现,KDM8与AR的互作能在雄激素缺乏条件下够导致雄激素响应基因表达的提高。这些基因包括ANCCA/ATAD2和EZH2,且是KDM8的直接靶标。这些基因还参与了激素缺乏条件下细胞生存的维持。明显的是,在恩杂鲁胺抗性细胞中,KDM8和EZH2的表达得到了进一步的提高,包括了神经内分泌标记。另外,EZH2抑制剂或者KDM8的敲除均能够使得细胞对恩杂鲁胺重新敏感。在细胞质中,KDM8与PKM2互作,可作为丙酮酸盐流开关控制因子,还可以将PKM2转运到细胞核中,且KDM8/PKM2复合物可作为HIF-1α得共激活子上调糖酵解基因的表达。最后,研究人员利用shRNA敲除确定了KDM8作为雄激素响应和代谢基因调控因子的功能。

最后,研究人员指出,KDM8是前列腺癌细胞代谢适应和去势抗性的理想治疗靶标。

原始出处:

Hung-Jung Wang, Mamata Pochampalli, Ling-Yu Wang et al. KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC. Oncogene. 2 Aug 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1746910, encodeId=cf6b1e46910b8, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Fri Aug 24 01:57:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049073, encodeId=9e8020490e31f, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Nov 12 01:57:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269607, encodeId=3a48126960ef4, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372299, encodeId=c50813e22994e, content=<a href='/topic/show?id=4e131432eda' target=_blank style='color:#2F92EE;'>#PKM2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14327, encryptionId=4e131432eda, topicName=PKM2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558126, encodeId=b556155812602, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569854, encodeId=49da1569854f3, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5279, encryptionId=bc1352e951, topicName=CRPC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5daa15584462, createdName=flyingeagle82, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338221, encodeId=667b33822196, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Aug 13 00:17:26 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2018-08-24 fusion
  2. [GetPortalCommentsPageByObjectIdResponse(id=1746910, encodeId=cf6b1e46910b8, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Fri Aug 24 01:57:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049073, encodeId=9e8020490e31f, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Nov 12 01:57:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269607, encodeId=3a48126960ef4, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372299, encodeId=c50813e22994e, content=<a href='/topic/show?id=4e131432eda' target=_blank style='color:#2F92EE;'>#PKM2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14327, encryptionId=4e131432eda, topicName=PKM2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558126, encodeId=b556155812602, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569854, encodeId=49da1569854f3, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5279, encryptionId=bc1352e951, topicName=CRPC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5daa15584462, createdName=flyingeagle82, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338221, encodeId=667b33822196, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Aug 13 00:17:26 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2018-11-12 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=1746910, encodeId=cf6b1e46910b8, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Fri Aug 24 01:57:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049073, encodeId=9e8020490e31f, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Nov 12 01:57:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269607, encodeId=3a48126960ef4, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372299, encodeId=c50813e22994e, content=<a href='/topic/show?id=4e131432eda' target=_blank style='color:#2F92EE;'>#PKM2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14327, encryptionId=4e131432eda, topicName=PKM2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558126, encodeId=b556155812602, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569854, encodeId=49da1569854f3, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5279, encryptionId=bc1352e951, topicName=CRPC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5daa15584462, createdName=flyingeagle82, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338221, encodeId=667b33822196, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Aug 13 00:17:26 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2018-08-14 rebeccajiejie
  4. [GetPortalCommentsPageByObjectIdResponse(id=1746910, encodeId=cf6b1e46910b8, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Fri Aug 24 01:57:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049073, encodeId=9e8020490e31f, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Nov 12 01:57:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269607, encodeId=3a48126960ef4, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372299, encodeId=c50813e22994e, content=<a href='/topic/show?id=4e131432eda' target=_blank style='color:#2F92EE;'>#PKM2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14327, encryptionId=4e131432eda, topicName=PKM2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558126, encodeId=b556155812602, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569854, encodeId=49da1569854f3, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5279, encryptionId=bc1352e951, topicName=CRPC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5daa15584462, createdName=flyingeagle82, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338221, encodeId=667b33822196, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Aug 13 00:17:26 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2018-08-14 by2009
  5. [GetPortalCommentsPageByObjectIdResponse(id=1746910, encodeId=cf6b1e46910b8, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Fri Aug 24 01:57:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049073, encodeId=9e8020490e31f, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Nov 12 01:57:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269607, encodeId=3a48126960ef4, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372299, encodeId=c50813e22994e, content=<a href='/topic/show?id=4e131432eda' target=_blank style='color:#2F92EE;'>#PKM2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14327, encryptionId=4e131432eda, topicName=PKM2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558126, encodeId=b556155812602, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569854, encodeId=49da1569854f3, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5279, encryptionId=bc1352e951, topicName=CRPC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5daa15584462, createdName=flyingeagle82, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338221, encodeId=667b33822196, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Aug 13 00:17:26 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1746910, encodeId=cf6b1e46910b8, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Fri Aug 24 01:57:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049073, encodeId=9e8020490e31f, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Nov 12 01:57:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269607, encodeId=3a48126960ef4, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372299, encodeId=c50813e22994e, content=<a href='/topic/show?id=4e131432eda' target=_blank style='color:#2F92EE;'>#PKM2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14327, encryptionId=4e131432eda, topicName=PKM2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558126, encodeId=b556155812602, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569854, encodeId=49da1569854f3, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5279, encryptionId=bc1352e951, topicName=CRPC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5daa15584462, createdName=flyingeagle82, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338221, encodeId=667b33822196, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Aug 13 00:17:26 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1746910, encodeId=cf6b1e46910b8, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Fri Aug 24 01:57:00 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049073, encodeId=9e8020490e31f, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Nov 12 01:57:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269607, encodeId=3a48126960ef4, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372299, encodeId=c50813e22994e, content=<a href='/topic/show?id=4e131432eda' target=_blank style='color:#2F92EE;'>#PKM2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14327, encryptionId=4e131432eda, topicName=PKM2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e2c339, createdName=by2009, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558126, encodeId=b556155812602, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569854, encodeId=49da1569854f3, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5279, encryptionId=bc1352e951, topicName=CRPC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5daa15584462, createdName=flyingeagle82, createdTime=Tue Aug 14 11:57:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338221, encodeId=667b33822196, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Aug 13 00:17:26 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2018-08-13 kafei

    学习了谢谢

    0

相关资讯

Sci Rep:在前列腺癌中,骨形态生成蛋白-2表达的减少与生化复发相关

最近,有研究人员在前列腺癌患者中利用免疫组化技术在前列腺癌组织中评估了BMP-2的表达的预后价值情况。研究人员在2007年7月到2010年8月之间,在患有局部前列腺癌(平均年龄,62.7岁;平均跟踪调查时间90.4个月)的90名患者的根治性前列腺切除样本中利用免疫组化技术评估了BMP-2的表达情况,并利用逐步多变量Cox回归模型分层方法评估了预测因素和评估的风险比(HRs)的独立效应。研究发现,在

N Engl J Med:恩杂鲁胺有效延缓未转移前列腺癌病情进展

对于那些未转移的去势抵抗性前列腺癌患者来说,如果出现PSA的迅速升高,则很可能预示着患者存在较高的转移风险,前期的研究已经证实,恩杂鲁胺可以延长转移性去势抵抗性前列腺癌患者的总体生存期,那么它是否能够同样有效于未转移的去势抵抗性前列腺癌呢?其对延缓此类患者的肿瘤转移时间和PSA升高情况能否起到更多的帮助呢?近日,Maha Hussain等人报道了他们关于此方面的临床研究[1],为此类病人的化疗

Cell:全面解锁不可用药的前列腺癌靶点

《Cell》报道,阻断核孔控制促癌分子流量即可限制侵袭性癌症发展。

Communications Biology:嵌合体ARCC-4靶向蛋白酶水解作用引起的雄激素受体降解要比恩杂鲁胺效果更好

雄激素受体是前列腺癌的一种主要驱使因子,利用竞争性拮抗剂对其转录活性的抑制,比如恩杂鲁胺,仍旧是前列腺癌治疗的一线疗法。然而,大多数的患者最终均发展出药物抗性。最近,有研究人员认为通过蛋白酶水解靶向嵌合体(PROTACs)来以雄激素受体为靶标使其降解,将会成为前列腺癌细胞中靶向雄激素受体信号疗法的一种更好的治疗性策略。研究人员在由一个当前批准的雄激素受体拮抗剂恩杂鲁胺和它的PROTAC衍生物ARC

Molecular Cell:全新发现,这款药物不仅可治疗卵巢癌、前列腺癌及胰腺癌还可治疗脑部疾病!

肌萎缩侧索硬化ALS是运动神经元疾病,病程晚期进展为全身肌肉萎缩和吞咽困难,最后产生呼吸衰竭,TDP-43是一个重要的致病相关蛋白,宾夕法尼亚研究小组发现PARP抑制剂可以阻止 PAR的产生,从而减少TDP-43的有害影响,此项研究发表在《Molecular Cell》上。

Sci Rep:前列腺癌中黄酮体受体研究

类固醇激素在前列腺中的致癌作用可以由它对前列腺癌(PCa)中的雄激素阻断治疗的影响来进行部分的解释。类固醇激素家族的其他成员,比如黄酮体,同样在PCa中具有一定的作用,但是黄酮体的作用仍旧没有明确的鉴定。最近,有研究人员调查了黄酮体受体亚型(PGRA和PGRB)在PCa组织中的分布,并调查了它们与临床终点的相关性。研究人员通过搜集535名患者的根治性前列腺切除样本进行了回顾性的研究,并利用组织芯片

Baidu
map
Baidu
map
Baidu
map